<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04551391</url>
  </required_header>
  <id_info>
    <org_study_id>ss</org_study_id>
    <secondary_id>MR/S01053X/1</secondary_id>
    <nct_id>NCT04551391</nct_id>
  </id_info>
  <brief_title>Kidney Recovery After Acute Kidney Injury - Longitudinal Study</brief_title>
  <acronym>KRAKIL</acronym>
  <official_title>Kidney Recovery After Acute Kidney Injury - Longitudinal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NHS Lothian</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NHS Lothian</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The endothelin (ET) system is an active target in human Acute Kidney Injury (AKI).&#xD;
&#xD;
      Our primary hypothesis is that the circulating blood concentration of ET will be higher in&#xD;
      patients with AKI than in matched controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute kidney injury (AKI) is a major health problem being both common and costly. It affects&#xD;
      ~20% of hospital inpatients and consumes ~1% of the annual NHS budget. AKI occurs following a&#xD;
      diverse range of insults, commonly ischaemia-reperfusion injury (IRI) but also sepsis and&#xD;
      drug toxicity. Therapies for AKI are currently supportive and short-term mortality remains&#xD;
      high, with ~2 million deaths per year worldwide. In those who survive an episode of AKI, 30%&#xD;
      are left with chronic kidney disease (CKD). The remaining 70% that recover full renal&#xD;
      function are at ~28-fold increased risk of ultimately developing CKD. This risk is even&#xD;
      greater in elderly patients. Importantly, CKD is strongly and independently associated with&#xD;
      incident cardiovascular disease (CVD), and together these exert a global socioeconomic&#xD;
      burden.&#xD;
&#xD;
      The recognition that AKI and CKD are linked is recent and the molecular pathways that control&#xD;
      the transition from acute injury to chronic disease are not well defined. Currently, there&#xD;
      are no specific treatments that reduce the risk of progressing to CKD after AKI. Thus, there&#xD;
      is an unmet need for therapies that will prevent the transition from AKI to CKD and reduce&#xD;
      the cardiovascular burden associated with both. Our preliminary investigations (not yet&#xD;
      published) in humans and mice suggest that AKI causes sustained activation of the endothelin&#xD;
      (ET) system to the long-term detriment of renal and systemic haemodynamic function. These&#xD;
      pilot data form the basis of our project that seeks to determine whether the ET system is&#xD;
      active in patients with AKI and, thus, represents a potential target for therapeutic&#xD;
      intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To primary outcome aims to measure whether circulating ET is higher in patients with AKI than in matched controls.</measure>
    <time_frame>3 years</time_frame>
    <description>as above</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary outcome aims to measure differences in urine ET between patients with AKI and matched controls AKI patients that do not fully recover renal function within 90 days will have the highest concentrations of blood and urine ET.</measure>
    <time_frame>3 YEARS</time_frame>
    <description>as above</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Case</arm_group_label>
    <description>(i) Adult aged 16 or over; (ii) Ability to provide informed consent; (iii) Diagnosis of AKI determined as:&#xD;
Previous (within 3 years) eGFR &gt;45 mL/min/1.73m2 OR no history of kidney disease if no recent (within 3 years) blood results available AND&#xD;
Elevated creatinine over 1.5 x previous result OR over 150 μmol/L if no previous value AND&#xD;
Increasing creatinine &gt;= 27μmol/L above index value within 48 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>(i) Adult aged 16 or over; (ii) Ability to provide informed consent; (iii) Admitted to hospital without AKI: (eGFR &gt; 60).&#xD;
This group will be recruited contemporaneously with, and matched to, AKI participants by:&#xD;
Age (± 5 years)&#xD;
Sex&#xD;
AKI aetiology (ischaemic, infected, nephrotoxic) 4 (i) History of diabetes or not AND/OR (ii) History of cardiovascular disease or not</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood and urine sampling</intervention_name>
    <description>Retinal OCT is a novel, non-invasive method for cross-sectionally imaging the eye's retina and choroid</description>
    <arm_group_label>Case</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>retinal opticla coherence tomography</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Circulating blood concentration of endothelin and urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        (i) Adult aged 16 or over; (ii) Ability to provide informed consent; (iii) Diagnosis of AKI&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        (i) Adult aged 16 or over; (ii) Ability to provide informed consent; (iii) Diagnosis of AKI&#xD;
        determined as:&#xD;
&#xD;
          -  Previous (within 3 years) eGFR &gt;45 mL/min/1.73m2 OR no history of kidney disease if no&#xD;
             recent (within 3 years) blood results available AND&#xD;
&#xD;
          -  Elevated creatinine over 1.5 x previous result OR over 150 μmol/L if no previous value&#xD;
             AND&#xD;
&#xD;
          -  Increasing creatinine &gt;= 27μmol/L above index value within 48 hours&#xD;
&#xD;
        The control group (N=50) inclusion criteria are:&#xD;
&#xD;
        (i) Adult aged 16 or over; (ii) Ability to provide informed consent; (iii) Admitted to&#xD;
        hospital without AKI: (eGFR &gt; 60)&#xD;
&#xD;
        This group will be recruited contemporaneously with, and matched to, AKI participants by:&#xD;
&#xD;
          1. Age (± 5 years)&#xD;
&#xD;
          2. Sex&#xD;
&#xD;
          3. AKI aetiology (ischaemic, infected, nephrotoxic) 4 (i) History of diabetes or not&#xD;
             AND/OR (ii) History of cardiovascular disease or not&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to provide informed consent&#xD;
&#xD;
          2. Prisoners&#xD;
&#xD;
          3. Pregnancy or breast feeding&#xD;
&#xD;
          4. Evidence of CKD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>James Dear, BMBchBSc PhD MRCP</last_name>
    <phone>01312421284</phone>
    <email>james.dear@ed.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel O'Brien, BA, BN</last_name>
    <phone>01312423867</phone>
    <email>rachel.o'brien@nhslothian.scot.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NHS Lothian</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Dear</last_name>
      <email>james.dear@ed.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Rachel O'Brien</last_name>
      <email>rachel.o'brien@nhslothian.scot.nhs.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 3, 2020</study_first_submitted>
  <study_first_submitted_qc>September 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

